Companies Dominating the Blood Screening Landscape
- Abbott Laboratories
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Grifols, S.A.
- Quotient Limited
- Thermo Fisher Scientific Inc.
- BD
- Ortho Clinical Diagnostics
- DiaSorin S.p.A.
- Bio-Rad Laboratories, Inc.
- Danaher Corporation
- Beckman Coulter, Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Currently in 2025, the industry revenue of blood screening is assessed at USD 3.14 billion.
The global blood screening market is projected to grow from USD 3 billion in 2024 to USD 6.8 billion by 2037, reflecting a CAGR of over 6.5% during the forecast period, from 2025 to 2037.
North America industry is poised to hold largest revenue share of 38% by 2037, driven by higher demand for blood transfusion in the region.
The major players in the market include Abbott Laboratories, Grifols, S.A., Quotient Limited, Thermo Fisher Scientific Inc., BD, Ortho Clinical Diagnostics, DiaSorin S.p.A., Bio-Rad Laboratories, Inc., Danaher Corporation, Beckman Coulter, Inc.
